INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $273,000 | – | 2,200 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $39,083,000 | 9.04% |
| Senvest Management, LLC | 1,152,032 | $70,873,000 | 5.40% |
| Melqart Asset Management (UK) Ltd | 298,200 | $18,345,000 | 2.20% |
| Elk Creek Partners, LLC | 348,454 | $21,437,000 | 1.25% |
| ALTRINSIC GLOBAL ADVISORS LLC | 375,223 | $23,084,000 | 0.93% |
| BB BIOTECH AG | 545,719 | $33,573,000 | 0.93% |
| Virtus ETF Advisers LLC | 14,681 | $903,000 | 0.78% |
| Opus Point Partners Management, LLC | 4,496 | $277,000 | 0.54% |
| Spark Investment Management LLC | 136,500 | $8,397,000 | 0.54% |
| Regal Investment Advisors LLC | 29,511 | $1,816,000 | 0.40% |